Last reviewed · How we verify
Quetiapine Fumarate Sustained Release
Quetiapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors in the brain.
Quetiapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Major depressive disorder (adjunctive therapy).
At a glance
| Generic name | Quetiapine Fumarate Sustained Release |
|---|---|
| Also known as | Seroquel XR |
| Sponsor | AstraZeneca |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Quetiapine blocks dopamine and serotonin receptors, which reduces psychotic symptoms and stabilizes mood. The sustained-release formulation provides extended drug delivery over 24 hours, allowing once-daily dosing while maintaining therapeutic levels. This mechanism is thought to normalize neurotransmitter activity in brain regions associated with psychosis, mania, and depression.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute mania and maintenance)
- Major depressive disorder (adjunctive therapy)
Common side effects
- Somnolence/sedation
- Dry mouth
- Dizziness
- Weight gain
- Headache
- Constipation
- Tachycardia
Key clinical trials
- SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia (PHASE3)
- Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia (PHASE3)
- Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia (PHASE3)
- Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo (PHASE3)
- Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder (PHASE3)
- A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome (PHASE4)
- Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder (PHASE3)
- Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quetiapine Fumarate Sustained Release CI brief — competitive landscape report
- Quetiapine Fumarate Sustained Release updates RSS · CI watch RSS
- AstraZeneca portfolio CI